CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase 2 Open Label Study to Investigate the Safety and Clinical Activity of Autologous EBV-specific T Cells (CMD-003) for the Treatment of Patients With EBV Positive Lymphomas

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT02763254
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:37:21.627844+00:00
Published At: 2019-03-12T00:00:00+00:00
Record Updated At: 2019-03-26
Results Posted At: 2019-03-12
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Hodgkin Lymphoma", "Lymphoma, Large B-Cell, Diffuse", "Post-transplant Lymphoproliferative Disorder"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2019-03-26"
protocolSection.identificationModule.nctId: "NCT02763254"
protocolSection.identificationModule.officialTitle: "A Phase 2 Open Label Study to Investigate the Safety and Clinical Activity of Autologous EBV-specific T Cells (CMD-003) for the Treatment of Patients With EBV Positive Lymphomas"
protocolSection.statusModule.overallStatus: "TERMINATED"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2019-03-12"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.